JP Morgan 2024

R&D

JP Morgan 2024 – Sam Deutsch

In another lightning round JP Morgan interview, editor-in-chief Jonah Comstock caught up with Sam Deutsch, CEO of Nutcracker Therapeutics, to talk briefly about the company’s lead asset for cervica

R&D

JP Morgan 2024 – Jonah Comstock interview with Xavier Duportet

JP Morgan 2024 – Xavier Duportet

There were plenty of gene therapy companies around at JP Morgan 2024, and more than a few companies focused on the microbiome.

R&D

JP Morgan interview with Jonah Comstock and Marianne De Backer

JP Morgan 2024 – Marianne De Backer

Vir Biotechnology made headlines in 2021 for its work with GlaxoSmithKline on a treatment for COVID-19, and again in 2022 for its work with the US government on influenza.

R&D

JP Morgan 2024 – Jonah Comstock talks with Trevor Martin

JP Morgan 2024 – Trevor Martin

Editor-in-chief Jonah Comstock caught up with Trevor Martin, co-founder and CEO of Mammoth Biosciences

Digital

JP Morgan 2024 – Simon Arkell

Generative AI – large language models, or LLMs, like ChatGPT – has the potential to revolutionise almost any knowledge industry, and pharma is no exception.

R&D